Absentia Labs addresses the most expensive and failure-prone stage of drug development: pre-clinical testing. Pharma spends over $15 billion yearly on outdated, slow, and ethically problematic methods, with 95% of drug candidates failing to be effective in humans. Our customers seek a scalable, more predictive alternative. With increasing support from the FDA, NIH, and EPA, the $58 billion early-stage R&D market is ready for innovation. Our AI-based whole organism platform allows for quicker, safer decision-making—eliminating the need for animal testing.